Idiopathic normal pressure hydrocephalus (iNPH) is a common disorder in aging populations. Alzheimer's disease (AD) is a significant comorbidity in iNPH patients, and the presence of AD pathology is associated with worse shunting outcomes. Cerebrospinal fluid (CSF) concentrations of AD-associated biomarkers in iNPH patients are universally reduced and the exact mechanism related to this is unknown.
Objective
Our aim was to study the effects of ventricular volume on CSF AD-associated biomarker levels in iNPH patients, to determine whether a dilution effect occurs and to assess if brain AD pathology contributes to this effect.
Methods
A total of 153 iNPH patients had lumbar CSF samples available for analysis, along with brain MRIs of sufficient quality. Automated image analysis software was used to determine the volume of different brain segments. Volumes normalized for age, sex and head size were used for analysis. Brain biopsy data on AD pathology was also available.
Results
None of the intracerebral ventricular volumes correlated with CSF levels of AD-associated biomarkers, indicating no dilution effect was present in this context. However, in iNPH patients positive for amyloid-β pathology in the biopsy, the volume of the fourth ventricle correlated inversely with all investigated biomarkers.
Conclusions
Intracerebral ventricular volumes do not correlate with AD biomarker levels in CSF, arguing against a dilution effect. However, in patients with AD pathology, the volume of the fourth ventricle is inversely correlated with CSF T-Tau and P-Tau181 levels, suggesting a complex relationship between brain AD pathology, CSF flow and CSF volume in iNPH patients.
RelkinNMarmarouAKlingeP, et al.INPH Guidelines, part II: diagnosing idio-pathic normal-pressure hydrocephalus. Neurosurgery2005; 57: 4–16.
2.
NakajimaMYamadaSMiyajimaM, et al.Guidelines for management of idiopathic normal pressure hydrocephalus (third edition): endorsed by the Japanese society of normal pressure hydrocephalus. Neurol Med Chir (Tokyo)2021; 61: 63–97.
3.
AnderssonJRosellMKockumK, et al.Prevalence of idiopathic normal pressure hydrocephalus: a prospective, population based study. PLoS One2019; 14: e0217705.
4.
IsekiCTakahashiYAdachiM, et al.Prevalence and development of idiopathic normal pressure hydrocephalus: a 16-year longitudinal study in Japan. Acta Neurol Scand2022; 146: 680–689.
5.
LucianoMHolubkovRWilliamsMA, et al.Placebo-controlled effectiveness of idiopathic normal pressure hydrocephalus shunting: a randomized pilot trial mark. Neurosurgery2023; 92: 481–489.
6.
AndrénKWikkelsøCHellströmP, et al.Early shunt surgery improves survival in idiopathic normal pressure hydrocephalus. Eur J Neurol2021; 28: 1153–1159.
7.
LuikkuAJHallANergO, et al.Predicting development of Alzheimer’s disease in patients with shunted idiopathic normal pressure hydrocephalus. J Alzheimer’s Dis2019; 71: 1233–1243.
8.
GoldDWisialowskiCPiryatinskyI, et al.Longitudinal post-shunt outcomes in idiopathic normal pressure hydrocephalus with and without comorbid Alzheimer’s disease. J Int Neuropsychol Soc2023; 29: 751–762.
9.
ScheltensPDe StrooperBKivipeltoM, et al.Alzheimer’s disease. Lancet2021; 397: 1577–1590.
10.
JackCRKnopmanDSJagustWJ, et al.Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol2013; 12: 207–216.
11.
van DyckCHSwansonCJAisenP, et al.Lecanemab in early Alzheimer’s disease. N Engl J Med2023; 388: 9–21.
12.
SimsJRZimmerJAEvansCD, et al.Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA2023; 330: 512–527.
13.
PerneczkyRDomGChanA, et al.Anti-amyloid antibody treatments for Alzheimer’s disease. Eur J Neurol2024; 31: e16049.
14.
JuckerMWalkerLC. Alzheimer’s disease: from immunotherapy to immunoprevention. Cell2023; 186: 4260–4270.
15.
MahamanYAREmbayeKSHuangF, et al.Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention. Ageing Res Rev2022; 74: 101544.
16.
NganduTLehtisaloJSolomonA, et al.A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet2015; 385: 2255–2263.
17.
BlennowKZetterbergH. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med2018; 284: 643–663.
18.
DuboisBvon ArnimCAFBurnieN, et al.Biomarkers in Alzheimer’s disease: role in early and differential diagnosis and recognition of atypical variants. Alzheimers Res Ther2023; 15: 175.
19.
Graff-RadfordNR. Alzheimer CSF biomarkers may be misleading in normal-pressure hydrocephalus. Neurology2014; 83: 1573–1575.
20.
JeppssonAZetterbergHBlennowK, et al.Idiopathic normal-pressure hydrocephalus pathophysiology and diagnosis by CSF biomarkers. Neurology2013; 80: 1385–1392.
21.
LidénSFarahmandDLaurellK. Ventricular volume in relation to lumbar CSF levels of amyloid-β 1–42, tau and phosphorylated tau in iNPH, is there a dilution effect?Fluids Barriers CNS2022; 19: 59.
22.
LeinonenVRauramaaTJohanssonJ, et al.S-[18 F]THK-5117-PET and [11 C]PIB-PET imaging in idiopathic normal pressure hydrocephalus in relation to confirmed amyloid-β plaques and tau in brain biopsies. J Alzheimers Dis2018; 64: 171–179.
23.
JunkkariALuikkuAJDannerN, et al.The kuopio idiopathic normal pressure hydrocephalus protocol: initial outcome of 175 patients. Fluids Barriers CNS2019; 16: 21.
24.
KuboYKazuiHYoshidaT, et al.Validation of grading scale for evaluating symptoms of idiopathic normal-pressure hydrocephalus. Dement Geriatr Cogn Disord2007; 25: 37–45.
25.
LukkarinenHVanninenATesseurI, et al.Concordance of Alzheimer’s disease-related biomarkers between intraventricular and lumbar cerebrospinal fluid in idiopathic normal pressure hydrocephalus. J Alzheimers Dis2023; 91: 305–319.
26.
WillemseEAJvan MaurikISTijmsBM, et al.Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer’s disease biomarkers in a nonacademic, multicenter memory clinic cohort: the ABIDE project. Alzheimers Dement (Amst)2018; 10: 563–572.
27.
PyykköOTHelisalmiSKoivistoAM, et al.APOE4 Predicts amyloid-β in cortical brain biopsy but not idiopathic normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry2012; 83: 1119–1124.
28.
SeppäläTTNergOKoivistoAM, et al.CSF Biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology2012; 78: 1568–1575.
29.
KoikkalainenJRhodius-MeesterHTolonenA, et al.Differential diagnosis of neurodegenerative diseases using structural MRI data. Neuroimage Clin2016; 11: 435–449.
30.
LötjönenJMWolzRKoikkalainenJR, et al.Fast and robust multi-atlas segmentation of brain magnetic resonance images. Neuroimage2010; 49: 2352–2365.
31.
de OliveiraFFMiraldoMCde Castro-NetoEF, et al.Anthropometric and demographic features affect the interpretation of cerebrospinal fluid biomarkers in patients with different dementia syndromes and cognitively healthy adults. Neuromolecular Med2024; 26: 43.
32.
VisserPJReusLMGobomJ, et al.Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease. Mol Neurodegener2022; 17: 27.
33.
PatelMZhangYXiaoMF, et al.Neuronal pentraxin 2 correlates with neurodegeneration but not cognition in idiopathic normal pressure hydrocephalus (iNPH). Neurol Neurochir Pol2024; 58: 47–53.
34.
MaedaSOtaniTYamadaS, et al.Biomechanical effects of hyper-dynamic cerebrospinal fluid flow through the cerebral aqueduct in idiopathic normal pressure hydrocephalus patients. J Biomech2023; 156: 111671.
35.
EidePKValnesLMLindstrømEK, et al.Direction and magnitude of cerebrospinal fluid flow vary substantially across central nervous system diseases. Fluids Barriers CNS2021; 18: 16.
36.
AxellEHuJLindbergM, et al.The role of shear forces in primary and secondary nucleation of amyloid fibrils. Proc Natl Acad Sci U S A2024; 121: e2322572121.
37.
DunstanDEHamilton-BrownPAsimakisP, et al.Shear flow promotes amyloid-β fibrilization. Protein Eng Des Sel2009; 22: 741–746.
38.
TeohCLBekardIBAsimakisP, et al.Shear flow induced changes in apolipoprotein C-II conformation and amyloid fibril formation. Biochemistry2011; 50: 4046–4057.
39.
MakibatakeROdaSYagiY, et al.Amyloid-β slows cilia movement along the ventricle, impairs fluid flow, and exacerbates its neurotoxicity in explant culture. Sci Rep2023; 13: 13586.
40.
OlstadEWRingersCHansenJN, et al.Ciliary beating compartmentalizes cerebrospinal fluid flow in the brain and regulates ventricular development. Curr Biol2019; 29: 229–241.e6.
41.
PengSLiuJLiangC, et al.Aquaporin-4 in glymphatic system, and its implication for central nervous system disorders. Neurobiol Dis2023; 179: 106035.
42.
MorimotoYYoshidaSKinoshitaA, et al.Nonsense mutation in CFAP43 causes normal-pressure hydrocephalus with ciliary abnormalities. Neurology2019; 92: E2364–E2374.
43.
HuangSYZhangYRGuoY, et al.Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer’s disease. Alzheimers Dement2024; 20: 3251–3269.
44.
HarrisonIFIsmailOMachhadaA, et al.Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model. Brain2020; 143: 2576–2593.
45.
DüzelEBerronDSchützeH, et al.CSF Total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. Alzheimers Dement (Amst)2018; 10: 782–790.
46.
de SouzaLCChupinMLamariF, et al.CSF Tau markers are correlated with hippocampal volume in Alzheimer’s disease. Neurobiol Aging2012; 33: 1253–1257.
47.
JansenIEvan der LeeSJGomez-FonsecaD, et al.Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers. Acta Neuropathol2022; 144: 821–842.
48.
ContadorJPérez-MillánATort-MerinoA, et al.Longitudinal brain atrophy and CSF biomarkers in early-onset Alzheimer’s disease. Neuroimage Clin2021; 32: 102804.
49.
LiYRusinekHButlerT, et al.Decreased CSF clearance and increased brain amyloid in Alzheimer’s disease. Fluids Barriers CNS2022; 19: 21.
50.
RinneJOWongDFWolkDA, et al.Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. Acta Neuropathol2012; 124: 833–845.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
